Related Experiment Video

Updated: Apr 11, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review

Zebo Huang1, Yinxia Wu2, Xin Zhou1

  • 11Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, People's Republic of China.

Future Oncology (London, England)
|June 5, 2015
PubMed

Insights

mTOR inhibitors show limited efficacy as single agents or in combination therapies for solid tumors. Further research and novel drug development are crucial for improving cancer treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The mechanistic target of rapamycin (mTOR) signaling pathway is frequently dysregulated in various cancers, presenting a significant therapeutic target.
  • mTOR inhibitors are being investigated for their potential in oncotherapy.

Purpose of the Study:

  • To evaluate the clinical efficacy of mTOR inhibitors in solid tumors, excluding specific FDA-approved indications.
  • To identify the effectiveness of mTOR inhibitors as monotherapy and in combination regimens.

Main Methods:

  • Systematic analysis of 32 published clinical trials involving mTOR inhibitors.
  • Focus on solid tumors excluding renal cell cancer, neuroendocrine tumors, and metastatic breast cancer.

Main Results:

  • mTOR inhibitors demonstrated a lack of significant therapeutic effects when used as single agents.
  • Combination therapies involving mTOR inhibitors exhibited insufficient or minimal clinical activity.

Conclusions:

  • Current mTOR inhibitors show limited clinical utility in the studied solid tumor types.
  • Further investigation into the clinical effects of mTOR inhibitors is warranted.
  • Development of novel mTOR inhibitors is essential for advancing cancer treatment.
Keywords:
clinical trialsmTOR inhibitorsolid tumor

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K
Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

20.1K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K